Surgery Partners (NASDAQ:SGRY) Posts Earnings Results, Beats Expectations By $0.01 EPS

Surgery Partners (NASDAQ:SGRY) announced its quarterly earnings results on Monday. The company reported $0.39 earnings per share for the quarter, beating analysts’ consensus estimates of $0.38 by $0.01, Zacks reports. Surgery Partners had a negative net margin of 2.03% and a positive return on equity of 2.85%. Surgery Partners updated its FY 2025 guidance to EPS.

Surgery Partners Price Performance

NASDAQ:SGRY opened at $24.08 on Monday. The business’s 50-day simple moving average is $23.04 and its two-hundred day simple moving average is $26.45. Surgery Partners has a 52 week low of $19.50 and a 52 week high of $33.97. The stock has a market cap of $3.06 billion, a PE ratio of -50.17, a P/E/G ratio of 19.21 and a beta of 2.60. The company has a quick ratio of 1.66, a current ratio of 1.80 and a debt-to-equity ratio of 0.99.

Analyst Ratings Changes

A number of analysts recently weighed in on the stock. JPMorgan Chase & Co. dropped their price objective on shares of Surgery Partners from $38.00 to $28.00 and set a “neutral” rating on the stock in a report on Tuesday, December 3rd. Macquarie reiterated an “outperform” rating and set a $34.00 price target on shares of Surgery Partners in a report on Tuesday, November 19th. Bank of America assumed coverage on Surgery Partners in a research note on Monday, December 16th. They issued a “buy” rating and a $30.00 target price for the company. Finally, Royal Bank of Canada reduced their price objective on Surgery Partners from $49.00 to $35.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, three have assigned a hold rating and seven have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $36.56.

Insider Buying and Selling

In related news, CFO David T. Doherty sold 13,641 shares of the stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $25.61, for a total value of $349,346.01. Following the sale, the chief financial officer now directly owns 108,862 shares of the company’s stock, valued at $2,787,955.82. This represents a 11.14 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, insider Harrison R. Bane sold 56,315 shares of the business’s stock in a transaction on Friday, February 7th. The shares were sold at an average price of $25.64, for a total transaction of $1,443,916.60. Following the sale, the insider now directly owns 107,037 shares of the company’s stock, valued at $2,744,428.68. This represents a 34.47 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 96,733 shares of company stock worth $2,480,106. 2.30% of the stock is owned by insiders.

Surgery Partners Company Profile

Surgery Partners, Inc, together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery.